MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $73.1429.

A number of research firms have recently commented on MLTX. Wedbush reiterated an “outperform” rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Redburn Atlantic raised MoonLake Immunotherapeutics to a “hold” rating in a report on Monday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Finally, Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a “peer perform” rating to an “outperform” rating and set a $61.00 price target for the company in a research report on Monday, May 19th.

Institutional Trading of MoonLake Immunotherapeutics

Institutional investors have recently bought and sold shares of the company. Deutsche Bank AG boosted its position in shares of MoonLake Immunotherapeutics by 59.8% in the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after buying an additional 338 shares in the last quarter. US Bancorp DE raised its position in MoonLake Immunotherapeutics by 114.4% during the first quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after acquiring an additional 1,178 shares during the last quarter. Quarry LP purchased a new stake in shares of MoonLake Immunotherapeutics in the first quarter valued at about $94,000. Advisors Asset Management Inc. lifted its holdings in shares of MoonLake Immunotherapeutics by 81.7% in the first quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock valued at $157,000 after purchasing an additional 1,803 shares in the last quarter. Finally, Birchview Capital LP acquired a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at approximately $217,000. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Stock Up 0.8%

MLTX stock opened at $53.32 on Thursday. The company’s 50 day moving average price is $47.75 and its 200 day moving average price is $42.92. The firm has a market capitalization of $3.41 billion, a price-to-earnings ratio of -23.18 and a beta of 1.27. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 21.11 and a current ratio of 21.11.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period in the previous year, the business posted ($0.22) earnings per share. On average, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.